2014-03-13 12:28:46 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Skystar Bio-Pharmaceutical Company (SKBI) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Skystar Bio-Pharmaceutical Company (SKBI). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Skystar Bio-Pharmaceutical Company investor.
Report Summary: Skystar Bio-Pharmaceutical Company is an average quality company with a positive outlook. Skystar Bio-Pharmaceutical Company has medium business growth and is run by efficient management. The trend in Skystar Bio-Pharmaceutical Company fair value exchange rate against its closest rated-competitor, Novogen Limited (ADR), has been appreciating over the past 2 weeks. When compared to its closest competitor, Skystar Bio-Pharmaceutical Company shows similar overvaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of Skystar Bio-Pharmaceutical Company for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.